National Health Act 1953 - Determination under section 93 (PB No. 35 of 2006)

Administered by Department of Health, Disability and Ageing

Legislation au F2006L02521 Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

NATIONAL HEALTH ACT 1953

 

DETERMINATION UNDER SECTION 93

 

NO. PB 35 OF 2006

 

Purpose and operation

 

  1. The purpose of the Australian Pharmaceutical Benefits Scheme (PBS) is to provide    timely, reliable and affordable access for the Australian community to necessary and               cost-effective medicines.

 

2.                   The PBS is regulated by Part VII of the National Health Act 1953 (the Act), which  provides for the supply of listed drugs and medicinal preparations as pharmaceutical               benefits.

 

3.                   “Pharmaceutical benefit” is defined under subsection 84(1) of the Act as  a drug or medicinal preparation in relation to which, by virtue of section 85 of the Act, Part VII of the Act applies.

 

4.                   Section 93 of the Act provides for the supply of certain pharmaceutical benefit items to medical practitioners as an emergency drug supply.  These drugs are supplied free of charge to patients.

 

5.                   Subsection 93(1) of the Act provides that, except as prescribed, a medical practitioner is authorised to supply such pharmaceutical benefits as the Minister determines to persons who are entitled under Part VII of the Act to receive those pharmaceutical benefits.

 

6.                   Subsection 93(2) of the Act provides that the Minister may determine the maximum quantity or number of units of a pharmaceutical benefit which may be obtained by a medical practitioner during a specified period and that the medical practitioner shall obtain the pharmaceutical benefit as prescribed.             

 

7.                   The determination under section 93 of the Act sets out the conditions under which a medical practitioner is authorised to supply emergency drugs as pharmaceutical benefits.

 

8.                   The Schedule to the determination lists the names of the pharmaceutical benefits to which section 93 applies, together with the form (strength type, size etc.) and maximum quantity of those pharmaceutical benefits.

 

9.                   The determination made under section 93 of the Act on 24 March 2006 with effect from 1 April 2006 (No. PB 18 of 2006) is repealed and substituted with this determination.

 


10.              This determination is remade to give effect, as from 1 August 2006, to changes to the list of drugs and medicinal preparations available as pharmaceutical benefits, as recommended by the Pharmaceutical Benefits Committee.

 

11.              This determination is remade in order to give effect to the following changes to the list of items available as doctor’s bag supplies :

  •               Increase in the Maximum Quantity to 20 for Diptheria and Tetanus Vaccine –               Adsorbed (Diluted), injection 0.5 mL in pre-filled syringe. This increase was               recommended by the Pharmaceutical Benefits Advisory Committee.  

 

Consultations

 

12.              The Pharmaceutical Benefits Advisory Committee (PBAC) is the independent expert body, established by section 100A of the Act, which makes recommendations to the Minister for Health and Ageing about which drugs and medicinal preparations should be available as pharmaceutical benefits.  Under subsection 101(4) of the Act, a drug or medicinal preparation may not be declared to be a drug or medicinal preparation to which Part VII of the Act applies unless the PBAC has recommended that it be so declared.  When recommending a medicine be listed on the PBS, the PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.

 

13.              The determination gives effect to recommendations made by the PBAC.  PBAC members are selected from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions.  Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC.

 

14.              Details of the determination are set out in the Attachment.

 

15.              This determination is a legislative instrument for the purposes of the

 Legislative Instruments Act 2003.

 

16.              The determination was made on 26 July 2006 and commenced on 1 August 2006.


ATTACHMENT

 

Paragraph 1 provides that this determination commences on 1 August 2006.

 

Paragraph 2 provides that the determination under section 93 of the National Health Act 1953 (the Act) made on 24 March 2006 (No. PB 18 of 2006) is repealed.

 

Paragraph 3 provides that the Schedule to the determination lists those pharmaceutical benefits to which section 93 applies (emergency supply drugs).

 

Paragraph 4 provides that where a medical practitioner has obtained drugs under section 93 of the Act, that medical practitioner, or a locum acting on that medical practitioner’s behalf, may supply those drugs.

 

Paragraph 5 provides that the medical practitioner may not obtain more than the maximum quantity or number of units of a drug in any one month, the maximum quantity or number of units being specified in the Schedule to this determination.

 

Paragraph 6 provides that, if the medical practitioner has obtained a quantity of drugs under section 93 of the Act, and is in possession of a quantity that is equal to or more than the maximum quantity of that drug (as specified in the Schedule), that medical practitioner may not obtain a further quantity of that drug.

 

The Schedule to the determination lists the names of the pharmaceutical benefits to which section 93 applies, together with the form (strength type, size etc.) and maximum quantity of those pharmaceutical benefits.

 

Overview

The National Health Act 1953, enacted by the Parliament of Australia, serves to regulate the Australian Pharmaceutical Benefits Scheme (PBS), ensuring timely, reliable, and affordable access to necessary and cost-effective medicines for the Australian community. This legislation is designed to provide pharmaceutical benefits to patients, allowing medical practitioners to supply certain drugs and medicinal preparations as benefits under the scheme. The Act was introduced to address the need for a structured and accessible system to ensure that essential medications are available and affordable to the public. The policy objective is to provide equitable access to medications that are deemed necessary and cost-effective, overseen by the Pharmaceutical Benefits Advisory Committee (PBAC), which makes recommendations to the Minister for Health and Ageing based on clinical effectiveness, safety, and cost-effectiveness. This determination under section 93 of the Act, made on 26 July 2006 and commencing on 1 August 2006, updates the list of drugs and medicinal preparations available as pharmaceutical benefits, reflecting the recommendations made by the PBAC.

Scope and Application

The National Health Act 1953, through its Part VII, governs the Australian Pharmaceutical Benefits Scheme (PBS) which ensures timely, reliable and affordable access to necessary and cost-effective medicines for the Australian community. This Act applies to medical practitioners who are authorised to supply pharmaceutical benefits as emergency drugs, free of charge to patients, to individuals who are entitled under the Act to receive such benefits. The Minister for Health and Ageing determines the maximum quantity or number of units of a pharmaceutical benefit that a medical practitioner may obtain during a specified period. The Act's scope extends nationally, impacting healthcare providers and patients across Australia. The determination under section 93 of the Act, which sets out the conditions for the supply of these emergency drugs, is subject to change based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC, an independent expert body, advises the Minister on which drugs and medicinal preparations should be available as pharmaceutical benefits, taking into account clinical effectiveness, safety, and cost-effectiveness. The determination is a legislative instrument under the Legislative Instruments Act 2003 and includes a schedule listing the specific pharmaceutical benefits, their forms, and maximum quantities that can be supplied.

Key Provisions

The Australian Pharmaceutical Benefits Scheme (PBS) is regulated by Part VII of the National Health Act 1953. Under this framework, the Minister for Health is empowered to determine which pharmaceutical benefits can be supplied to medical practitioners for emergency use. The determination, as outlined in the Explanatory Statement, specifies the conditions under which medical practitioners can supply these emergency drugs to patients free of charge. These drugs are listed in the Schedule to the determination, which includes details such as the form (strength, type, size) and the maximum quantity that can be obtained. Medical practitioners are required to adhere to these conditions when obtaining and supplying emergency drugs. Specifically, they must ensure they do not exceed the specified maximum quantity or number of units of any drug during a given period, as outlined in the Schedule. If a medical practitioner has obtained the maximum allowable quantity of a drug, they are not permitted to obtain further supplies of that drug. This ensures that the distribution of emergency drugs is controlled and equitable, preventing any one practitioner from hoarding supplies at the expense of others. Failure to comply with the conditions set out in the determination can lead to legal consequences. Although the explanatory statement does not explicitly state the penalties for breach, under the National Health Act 1953, unauthorised supply of pharmaceutical benefits can lead to criminal charges. Penalties for such offences can include substantial fines and, in severe cases, imprisonment. The exact penalties would depend on the specific circumstances of the breach and would be determined by the courts. Additionally, medical practitioners found in breach of these provisions may face professional disciplinary actions, which could include suspension or revocation of their medical licence. The determination, by aligning with recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC), ensures that the emergency supply of drugs is based on clinical need and effectiveness. The PBAC’s role in recommending which drugs should be available as pharmaceutical benefits underscores the importance of expert input in maintaining the integrity and efficacy of the PBS. This expert body, comprising members from various healthcare-related fields, ensures that the recommendations are well-rounded and consider both medical and economic factors.

Legal classification tags

Area of Law
Health Law
Instrument
Legislative Instrument
Concepts
Definitions & Interpretation
Regulatory Standards
Licensing & Registration
Reporting & Disclosure Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.